Pharmacodynamic Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, from a Randomized Study in Patients with Type 2 Diabetes

• Sue Sha ,

  * E-mail: ssha@its.jnj.com

  Affiliation Janssen Research & Development, LLC, Raritan, NJ, United States of America

  ⨯
• Damayanthi Devineni,

  Affiliation Janssen Research & Development, LLC, Raritan, NJ, United States of America

  ⨯
• Atalanta Ghosh,

  Affiliation Janssen Research & Development, LLC, Raritan, NJ, United States of America

  ⨯
• David Polidori,

  Affiliation Janssen Research & Development, LLC, San Diego, CA, United States of America

  ⨯
• Marcus Hompesch,

  Affiliation Profil Institute for Clinical Research, Chula Vista, CA, United States of America

  ⨯
• Sabine Arnolds,

  Affiliation Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

  ⨯
• Linda Morrow,

  Affiliation Profil Institute for Clinical Research, Chula Vista, CA, United States of America

  ⨯
• Heike Spitzer,

  Affiliation Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

  ⨯
• Keith Demarest,

  Affiliation Janssen Research & Development, LLC, Raritan, NJ, United States of America

  ⨯
• Paul Rothenberg

  Affiliation Janssen Research & Development, LLC, Raritan, NJ, United States of America

  ⨯